Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Boehringer Ingelheim
Baxter
Johnson and Johnson
Harvard Business School

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEG 3350 AND ELECTROLYTES

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Peg 3350 And Electrolytes

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000574 Ibuprofen in Sepsis Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-09-01 To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.
NCT00000574 Ibuprofen in Sepsis Study Completed Vanderbilt University Medical Center Phase 3 1990-09-01 To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.
NCT00004328 Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I Completed University of Texas Phase 2 1992-12-01 OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic state in a patient with pseudohypoaldosteronism. II. Determine the effect of extracellular fluid volume and serum potassium manipulations on exercise tolerance, cardiac function, and endurance. III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
NCT00004328 Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I Completed National Center for Research Resources (NCRR) Phase 2 1992-12-01 OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic state in a patient with pseudohypoaldosteronism. II. Determine the effect of extracellular fluid volume and serum potassium manipulations on exercise tolerance, cardiac function, and endurance. III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
NCT00004360 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed Northwestern University N/A 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed National Center for Research Resources (NCRR) N/A 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Peg 3350 And Electrolytes

Condition Name

Condition Name for Peg 3350 And Electrolytes
Intervention Trials
Schizophrenia 11
Hypertension 8
Heart Failure 7
Multiple Myeloma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Peg 3350 And Electrolytes
Intervention Trials
Syndrome 16
Heart Failure 14
Hypertension 12
Schizophrenia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Peg 3350 And Electrolytes

Trials by Country

Trials by Country for Peg 3350 And Electrolytes
Location Trials
United States 254
Canada 33
China 26
United Kingdom 24
Israel 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Peg 3350 And Electrolytes
Location Trials
Texas 31
New York 23
California 20
Maryland 19
Missouri 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Peg 3350 And Electrolytes

Clinical Trial Phase

Clinical Trial Phase for Peg 3350 And Electrolytes
Clinical Trial Phase Trials
Phase 4 85
Phase 3 43
Phase 2/Phase 3 13
[disabled in preview] 118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Peg 3350 And Electrolytes
Clinical Trial Phase Trials
Completed 124
Recruiting 76
Not yet recruiting 36
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Peg 3350 And Electrolytes

Sponsor Name

Sponsor Name for Peg 3350 And Electrolytes
Sponsor Trials
University of Maryland 8
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 7
University of North Carolina, Chapel Hill 7
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Peg 3350 And Electrolytes
Sponsor Trials
Other 456
Industry 89
NIH 29
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Harvard Business School
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.